Clinical Edge Journal Scan

A new emollient regimen improves pruritus in atopic dermatitis


 

Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.

Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P = .0277) and worse pruritus over the last 24 hours after 42 days (P = .025) of treatment.

Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.

Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.

Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949

Recommended Reading

Atopic dermatitis positively linked with the risk for acne
MDedge Dermatology
Study focuses on adolescent data in upadacitinib AD trials
MDedge Dermatology
Commentary: Three New AD Treatments and a Study of Food Allergy, May 2023
MDedge Dermatology
Can this tool forecast peanut allergies?
MDedge Dermatology
Facial, hand, and foot dermatitis: Lebrikizumab and dupilumab show efficacy in new studies
MDedge Dermatology
Expunging ‘penicillin allergy’: Your questions answered
MDedge Dermatology
Upadacitinib shows a favorable benefit-risk profile in adolescents with moderate-to-severe atopic dermatitis
MDedge Dermatology
Tralokinumab effective against moderate-to-severe atopic dermatitis in adolescents
MDedge Dermatology
Crisaborole induces normalization of mild-to-moderate atopic dermatitis proteome
MDedge Dermatology
Real-world study affirms benefits of dupilumab in pediatric patients with uncontrolled atopic dermatitis
MDedge Dermatology